[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-prostatic-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-prostatic-obstruction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100053458","selective-median-lobe-surgery-outcomes-study-100053458",false,"NCT07699718","Selective Median Lobe Surgery Outcomes Study","UNVEIL-BPO Median Lobe Study: An International Multicenter Evaluation of Selective Median Lobe Resection and Enucleation","UNVEIL-BPO","Inclusion Criteria:\n\n* Male patients aged 45 years or older.\n\n  * Moderate-to-severe lower urinary tract symptoms due to benign prostatic obstruction or urinary retention requiring transurethral surgery.\n  * Preoperative findings suggesting median lobe-dominant or median lobe-related obstruction.\n  * Planned selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care.\n  * Available baseline International Prostate Symptom Score, uroflowmetry and\u002For postvoid residual volume, prostate volume, intravesical prostatic protrusion measurement, and cystoscopic assessment.\n  * Ability to provide written informed consent and comply with the follow-up schedule.\n\nExclusion Criteria:\n\n* Previous prostate surgery for benign prostatic hyperplasia.\n* Known urethral stricture requiring treatment before or during the index procedure.\n* Known neurogenic lower urinary tract dysfunction.\n* Active prostate cancer or bladder cancer requiring treatment that may confound urinary outcomes.\n* Planned complete TURP, complete HoLEP\u002FAEEP, or lateral lobe-dominant surgery.\n* Severe kissing lateral lobe obstruction considered to require complete surgery rather than selective median lobe surgery.\n* Inability to provide valid baseline or follow-up outcome data.","MALE","45 Years",{"count":20,"type":21},420,"ESTIMATED","OBSERVATIONAL","This prospective multicenter observational cohort study will evaluate clinical outcomes after selective median lobe transurethral surgery for benign prostatic obstruction. Eligible men with lower urinary tract symptoms or urinary retention who are scheduled for selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care will be enrolled and followed after surgery.\n\nThe study will collect preoperative clinical data, symptom scores, uroflowmetry, postvoid residual volume, prostate volume, intravesical prostatic protrusion measurements, cystoscopic anatomical findings, intraoperative variables, and postoperative outcomes. The primary outcome is composite clinical failure at 12 months.\n\nThe main aim is to identify practical preoperative urology-based anatomical and functional predictors of clinical failure after selective median lobe surgery and to develop an exploratory prediction model that may help improve patient selection in future practice.",[25,26,27,28,29],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Obstruction","Urinary Retention","Median Lobe Prostatic Enlargement",[31,32,33,34,35,36,37,38,39,40,41,42],"Median lobe","Intravesical prostatic protrusion","Selective median lobe surgery","Selective median lobe enucleation","Selective median lobe resection","TURP","HoLEP","Anatomical endoscopic enucleation of the prostate","Uroflowmetry","Postvoid residual","Clinical failure","Ejaculation preservation","NOT_YET_RECRUITING","2026-07-09",{"date":46,"type":47},"2026-07-13","ACTUAL",{"date":49,"type":21},"2026-09-01",{"date":51,"type":21},"2030-12-01",{"name":53,"class":54},"Necmettin Erbakan University","OTHER",2,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100641769","phase-4-tamsulosin-with-or-without-tadalafil-for-trial-without-catheter-after-acute-urinary-retention-due-to-benign-prostatic-hyperplasia-100641769","NCT07654413","Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia","Tamsulosin With Versus Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Prospective Double-Blind Randomized Trial","TAMS-TAD-TWOC","Inclusion Criteria:\n\n* Male patient aged 50 years or older.\n* First episode of spontaneous painful acute urinary retention.\n* Successful urethral catheterization at presentation.\n* Drained urine volume at presentation of at least 300 mL.\n* Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and\u002For ultrasound evidence of enlarged prostate.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Previous episode of acute urinary retention.\n* Chronic painless urinary retention phenotype.\n* Active urinary tract infection or sepsis.\n* Gross hematuria with clot retention.\n* Suspected or known urethral stricture.\n* Neurogenic bladder or major neurologic disease affecting voiding.\n* History of prostate cancer or bladder cancer.\n* Previous prostate surgery.\n* Current use of nitrates or guanylate cyclase stimulators.\n* Contraindication to tadalafil or tamsulosin.\n* Severe hypotension or unstable cardiovascular disease.\n* Severe renal impairment.\n* Severe hepatic impairment.\n* Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.","50 Years",{"count":66,"type":21},320,"INTERVENTIONAL",[69],"PHASE4","Acute urinary retention is a common emergency in men with benign prostatic hyperplasia. After bladder drainage with a urethral catheter, patients usually undergo a trial without catheter to determine whether they can pass urine again without recatheterization.\n\nThis study will evaluate whether adding tadalafil 5 mg once daily to tamsulosin 0.4 mg once daily improves the chance of successful trial without catheter in men with first-episode acute urinary retention due to presumed benign prostatic hyperplasia.\n\nParticipants will be randomly assigned to receive either tamsulosin plus tadalafil or tamsulosin plus a matching placebo. Study medication will start within 24 hours after catheterization. The catheter will be removed on Day 7. If the first trial without catheter fails, the catheter will be reinserted and a second rescue trial without catheter will be performed on Day 14.\n\nThe main outcome is overall catheter-free success by Day 14. Participants will also be followed for recurrent urinary retention, post-void residual urine, urinary flow, catheter-related complications, drug-related adverse events, and the need for benign prostatic hyperplasia-related surgery within 3 months.",[72,25,27],"Acute Urinary Retention",[74,75,76,77,25],"Trial Without Catheter","TWOC","Tamsulosin","Tadalafil","RECRUITING","2026-06-12",{"date":81,"type":47},"2026-06-17",{"date":83,"type":47},"2026-06-08",{"date":85,"type":21},"2027-12",{"name":87,"class":54},"Beni-Suef University",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":67,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":88},"100640142","ejaculation-preserving-versus-standard-bipolar-tuep-for-bph-100640142","NCT07629479","Ejaculation-Preserving Versus Standard Bipolar TUEP for BPH","Bipolar Transurethral Enucleation of the Prostate With Preservation of Ejaculation in Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Trial","EP-BTUEP","Inclusion Criteria:\n\n* Male patients with lower urinary tract symptoms secondary to benign prostatic obstruction after failed medical treatment for at least 3 months.\n* Sexually active patients with a continuous relationship with the same partner.\n* International Prostate Symptom Score of 8 or greater.\n* Transrectal ultrasound-estimated prostate size between 40 and 100 cc.\n* Eligible for bipolar transurethral enucleation of the prostate.\n* Ability to complete the required sexual and urinary function questionnaires.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative sexual dysfunction.\n* Preoperative ejaculatory dysfunction.\n* Diagnosis or suspicion of prostate cancer.\n* Neurological disorders affecting lower urinary tract or sexual function.\n* Detrusor hypocontractility.\n* Catheter-dependent patients.\n* Patients with bladder stones.\n* Inability or refusal to provide informed consent.",{"count":98,"type":21},60,[100],"NA","This prospective randomized controlled trial will compare ejaculation-preserving bipolar transurethral enucleation of the prostate with standard bipolar transurethral enucleation of the prostate in sexually active men with benign prostatic hyperplasia and lower urinary tract symptoms after failed medical treatment. Participants will be randomly assigned to either ejaculation-preserving B-TUEP or standard B-TUEP. The study will evaluate preservation of ejaculatory function, erectile function, urinary symptom improvement, uroflowmetry outcomes, post-void residual urine, perioperative complications, and need for retreatment during follow-up.",[25,103,27],"Lower Urinary Tract Symptoms",[105,106,42,107],"Bipolar transurethral enucleation of the prostate","B-TUEP","International Prostate Symptom Score","2026-06-01",{"date":110,"type":47},"2026-06-05",{"date":112,"type":47},"2025-09-08",{"date":114,"type":21},"2026-09",{"name":87,"class":54}]